Serum SHBG concentration was inversely associated with prostate cancer incidence (HR per 10 nmol/L increment = 0.95, 95% CI 0.94‐0.97; Ptrend < .0001, Figure 1), but was not associated with prostate cancer mortality (Figure 2). This evidence concerns the gene SHBG and prostate carcinoma.